Abstract: A contact lens treating solution includes (a) about 0.005 to about 2 wt. %, based on the total weight of the contact lens treating solution, of hyaluronic acid or a salt thereof; (b) about 0.01 to about 1 wt. %, based on the total weight of the contact lens treating solution, of erythritol; (c) one or more nonionic surfactants; (d) sodium chloride, potassium chloride or any combination thereof; and (e) one or more buffers.

Abstract: A preservative-free contact lens treating solution includes (a) about 0.005 to about 2 wt. %, based on the total weight of the preservative-free contact lens treating solution, of hyaluronic acid or a salt thereof; (b) about 0.01 to about 1 wt. %, based on the total weight of the preservative-free contact lens treating solution, of erythritol; (c) one or more nonionic surfactants; (d) sodium chloride, potassium chloride or any combination thereof; and (e) one or more buffers.

Abstract: A contact lens treating solution includes (a) about 0.005 to about 2 wt. %, based on the total weight of the contact lens treating solution, of hyaluronic acid or a salt thereof; (b) about 0.01 to about 1 wt. %, based on the total weight of the contact lens treating solution, of erythritol; (c) one or more nonionic surfactants; (d) sodium chloride, potassium chloride or any combination thereof; and (e) one or more buffers.

Abstract: A packaging system for the storage of an ophthalmic device is disclosed. The packaging system includes a sealed container containing one or more unused ophthalmic devices immersed in an aqueous packaging solution containing (a) one or more osmoprotectants, (b) one or more poloxamer comfort agents and (c) one or more polyol demulcents, wherein the aqueous packaging solution has an osmolality of at least about 150 mOsm/kg, a pH of about 6 to about 9 and is heat sterilized.

Abstract: A packaging system for the storage of an ophthalmic device is disclosed. The packaging system comprises a sealed container containing one or more unused ophthalmic devices immersed in an aqueous packaging solution comprising (a) one or more osmoprotectants, (b) one or more poloxamer comfort agents and (c) one or more polyol demulcents, wherein the aqueous packaging solution has an osmolality of at least about 150 mOsm/kg, a pH of about 6 to about 9 and is heat sterilized.

Abstract: An ophthalmically compatible solution includes (a) about 0.005 to about 2 wt. %, based on the total weight of the ophthalmically compatible solution, of hyaluronic acid or a salt thereof; (b) about 0.01 to about 1 wt. %, based on the total weight of the ophthalmically compatible solution, of erythritol; (c) sodium chloride, potassium chloride or any combination thereof; and (d) one or more buffers.

Abstract: An ophthalmically compatible solution includes (a) about 0.005 to about 2 wt. %, based on the total weight of the ophthalmically compatible solution, of hyaluronic acid or a salt thereof; (b) about 0.01 to about 1 wt. %, based on the total weight of the ophthalmically compatible solution, of erythritol; (c) sodium chloride, potassium chloride or any combination thereof; and (d) one or more buffers.

Abstract: A contact lens treating solution includes (a) about 0.005 to about 2 wt. %, based on the total weight of the contact lens treating solution, of hyaluronic acid or a salt thereof; (b) about 0.01 to about 1 wt. %, based on the total weight of the contact lens treating solution, of erythritol; (c) one or more nonionic surfactants; (d) sodium chloride, potassium chloride or any combination thereof; and (e) one or more buffers.

Abstract: A preservative-free contact lens treating solution includes (a) about 0.005 to about 2 wt. %, based on the total weight of the preservative-free contact lens treating solution, of hyaluronic acid or a salt thereof; (b) about 0.01 to about 1 wt. %, based on the total weight of the preservative-free contact lens treating solution, of erythritol; (c) one or more nonionic surfactants; (d) sodium chloride, potassium chloride or any combination thereof; and (e) one or more buffers.

Abstract: An ophthalmically compatible solution includes (a) about 0.005 to about 2 wt. %, based on the total weight of the ophthalmically compatible solution, of hyaluronic acid or a salt thereof; (b) about 0.01 to about 1 wt. %, based on the total weight of the ophthalmically compatible solution, of erythritol; (c) sodium chloride, potassium chloride or any combination thereof; and (d) one or more buffers.

Abstract: A packaging system for the storage of an ophthalmic device is disclosed. The packaging system comprises a sealed container containing one or more unused ophthalmic devices immersed in an aqueous packaging solution comprising (a) one or more osmoprotectants, (b) one or more poloxamer comfort agents and (c) one or more polyol demulcents, wherein the aqueous packaging solution has an osmolality of at least about 150 mOsm/kg, a pH of about 6 to about 9 and is heat sterilized.

Abstract: Ophthalmic composition that includes 0.05% w/v to 2% w/v diglycine or a salt thereof; 0.01 ppm to 3 ppm poly(hexamethylene biguanide); 1 ppm to 10 ppm ?-[4-tris(2-hydroxyethyl)ammonium chloride-2-butenyl]poly[1-dimethylammonium chloride-2-butenyl]-?-tris(2-hydroxyethyl)ammonium chloride; and 0.1% w/v to 2% w/v of one or more boron buffering compounds.

Abstract: Ophthalmic composition comprising one or more polyglycines selected from the group consisting of diglycine, triglycine, tetraglycine and pentaglycine, or the salts of each thereof and one or more boron buffering compounds. The ophthalmic composition will have an osmolality of from 200 mOsmol/kg to 420 mOsmol/kg.

Abstract: A method of retaining hyaluronic acid on a surface of a contact lens. The method comprises providing a contact lens care solution comprising; 0.005 wt. % to 0.05 wt. % of hyaluronic acid in a borate containing buffer, and 0.01 wt. % to 1.0 wt. % of an amphoteric surfactant of general formula I wherein R? is a C8-C16alkyl optionally substituted with hydroxyl; R2 and R3 are each independently selected from methyl, ethyl, propyl or iso-propyl; and R4 is a C2-C8alkylene optionally substituted with hydroxyl; and soaking the contact lens in the contact lens care solution for at least two hours prior to placement of the contact lens in an eye.

Abstract: A method for inhibiting adhesion of bacteria to a surface of a biomedical device is disclosed. The method involves at least (a) incorporating one or more non-functionalized polymers having one or more hydrophilic moieties into an ophthalmic device that is a polymerization product of a comonomer mixture comprising: (i) a major amount of a non-silicone-containing hydrophilic monomer; and (ii) an end-terminal functionalized surfactant; and (b) inserting the ophthalmic device in the eye of a patient, wherein the at least one non-functionalized polymer migrates to the surface of the device in a sustained release manner to inhibit adhesion of bacteria to a surface of the biomedical device. Biomedical devices are also disclosed.

Abstract: An aqueous ophthalmic composition comprising one or more terpene compounds, and one or more natural polymers selected from the group comprising hyaluronic acid, condroitin sulfate, alginate, guar gum, fructan, arabinogalactan or any corresponding salt or derivative of each thereof. The compositions can be used to disinfect or package a contact lens, or as an eye drop to comfort irritated eyes or rewet a contact lens.

Abstract: A process for covalently attaching an antimicrobial coating to a polymeric surface. The process comprises contacting the surface of the polymer with a plasma having reactive nitrogen compounds to provide a plasma-treated surface with —NHR groups, wherein R is hydrogen, hydroxyl or C1-2alkyl, reacting the —NHR groups with a surface linking agent, and attaching an amine-containing polymer to the linking agent to form the antimicrobial coating. The surface linking agent is selected from the group consisting of dihaloalkyl, a dihaloalkenyl, and a dihalomethylaryl. The invention is also directed to a contact lens case or a contact lens with an antimicrobial coating.

Abstract: Ophthalmic composition comprising one or more polyglycines selected from the group consisting of diglycine, triglycine, tetraglycine and pentaglycine, or the salts of each thereof and one or more boron buffering compounds. The ophthalmic composition will have an osmolality of from 200 mOsmol/kg to 420 mOsmol/kg.

Abstract: A method of treating a contact lens, and in some instances, a silicone hydrogel contact lens, in the eye of a wearer comprising i) applying to said contact lens and/or eye an ophthalmically compatible contact lens cleaning and/or hydrating and/or disinfecting solution; and ii) rubbing the eyelid associated with said eye over the contact lens for at least about one second.